^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell Lymphoma

Published date:
11/06/2019
Excerpt:
...phase II study for pts with relapsed or refractory (RR) PTCL or CTCL...The most notable finding was that responders to ruxolitinib had markedly lower pS6 expression within tumor cells of pre-treatment biopsies…
DOI:
10.1182/blood-2019-125017